Hutchmed files for $600M+ IPO in Hong Kong as lead oncology drug surufatinib awaits FDA’s good graces

In oncology, a flush of Chinese-developed drugs has the biopharma industry rethinking the poles of power in R&D as the blossoming nation continues to make a name for itself and pick up bundles of cash in the process. Now, as its lead drug faces a pivotal FDA review, the company...

Click to view original post